This announcement does not concern the awarding of a public contract within the meaning of the procurement coordination directive (2014/24 / EU) or antitrust law. In the interest of the broadest possible information for interested pharmaceutical companies, this announcement is made in the supplement to the Official Journal of the European Union. The procedure designation "open procedure" used in the context of the present notice text (section IV.1.1) is due to the requirements of the notice form. This, as well as the use of the medium "TED", does not imply any submission to procurement law regulations, the validity of which is not mandatory by law or procurement regulations. It is a framework contract with an accession option that relates to various active ingredients.

The contract covers medicinal products that contain the active ingredient bevacizumab.

The contract covers medicinal products that contain the active ingredient prednisolone (ophthalmic).

The contract covers drugs that contain the active ingredient promethazine.

The contract covers drugs that contain the active ingredient roflumilast.

The contract covers medicinal products that contain the active ingredient tofacitinib.

The contract covers medicinal products that contain the active ingredient botulinum toxin (without Lifestyle AM).

The contract covers medicinal products that contain the drug combination candesartan and amlodipine.

The contract covers drugs that contain the combination of active ingredients enalapril and lercanidipine.

The contract covers medicinal products that contain the active ingredient epinephrine (without OTC).

The contract covers drugs that contain the active ingredient infliximab iv.

The contract covers drugs that contain the active ingredient infliximab sc.

The contract covers medicinal products that contain the active ingredient lormetazepam.

The contract covers drugs that contain the active ingredient combination perindopril and amlodipine.